N/A N=72 For the Health of Our Children--Clinic Based Treatment of Childhood Obesity
Obesity
Primary: Body Mass Index Z-score Change — -0.02; -0.08 BMI z-score change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=486 Determining Age Appropriateness of Children's Products and Toys
Healthy Volunteers Only
Primary: Utilization of Toy — .45; .49; .50; .53 Proportion
N/A N=5,392 Impact of Body Weight on the Immediate Health of the Pediatric Population
Childhood Obesity
Primary: Diagnosis of Infectious Disease — 900; 1067 Participants — p=.026
N/A N=10 Healthy Kids I-PAL
Childhood Obesity
Primary: Child Acceptability of the mHealth Approach — 3.8 score on a scale
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=138 Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
Meningococcal Disease · Infections, Meningococcal
Primary: Number of Subjects Who Experienced Single or Multiple Medical Encounters — 16; 24 Participants
N/A N=127 Iron Treatment for Young Children With Non-anemic Iron Deficiency
Non-anemic Iron Deficiency
Primary: Early Learning Composite (ELC) From the Mullen Scales of Early Learning — 113.0; 113.5; 110.48; 107.94 units on a scale
Phase 2 N=461 Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
Infections, Meningococcal
Primary: Number of Subjects With an Immune Response to Different Meningococcal Serogroups — 30; 32; 26; 27 Participants
Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants
Phase 3 N=1,200 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (≥) 0.35 Micrograms Per…
N/A N=642 Validation of the Mercy TAPE
Weight
Primary: Predictive Performance of the Mercy TAPE (Percent of Participants Predicted Within 20% of Their Actual Weight) — 98.1; 93.3 percentage of participants
Phase 4 N=60 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
Influenza
Primary: Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions Following Vaccination With the 2014-2015 Formulation of Fluzone® Quadrivalent…
Phase 4 N=60 Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2015-2016 Formulation of Fluzone® Quadrivalent…
N/A N=352 Population Effects of MI on Pediatric Obesity in Primary Care
Pediatric Obesity
Primary: Percent Distance From the Sex-age Specific 95th Percentile — 106.4; 102.7 % distance from 95th percentile
N/A N=251 Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Phase 4 N=32 Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
Influenza · Orthomyxoviridae Infections
Primary: Number of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination 1 — 10; 2; 2; 1 Participants
Phase 4 N=30 Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
Influenza
Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition Antibodies Pre-vaccination and 14 Days Post-vaccination — 5.0; 8.2; 187.8; 95.1 Titer
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 2 N=531 Sanofi Pasteur, TIV + H1N1, Pediatric Population
Influenza
Primary: Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
N/A N=715 Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers
Feeding and Eating Disorders of Childhood
Primary: Exclusive Breastfeeding at Four Months of Age — 140; 104 Participants
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
N/A N=7 Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit
Growth & Development · Child Development · Internship and Residency
Primary: Presence of Resident Surveillance Behaviors of Specific Aspects of Developmental Status at the Two Month Preventive Care Visit — 3 Participants
N/A N=1,235 Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Health Care Utilization · Vaccine Preventable Disease
Primary: Number of Participants Who Completed an Adolescent Well-care Visit — 43; 56; 55 Participants — p=0.165
N/A N=34 Healthy Start to Feeding Intervention
Weight, Body · Diet Habit
Primary: Weight-for-Length Percentile — 44.94; 46.70; 58.69; 48.54 Percentile
N/A N=95 Validation of a Food Frequency Questionnaire
Nutrition
Primary: Validated Food Frequency Questionnaire — 0.39; 0.35; 0.28; 0.32 Pearson correlation
Phase 3 N=112 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
SARS-CoV-2 Infection, COVID-19
Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age — 12.5; 0; 100.0; 16.7 Percentage of participants
N/A N=50 Guided Self-help for Families With an Overweight Child
Obesity
Primary: Child BMI — 23.3; 25.17 kg/m^2
N/A N=108 Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department
Fever
Primary: Number of Participants With Admission to Hospital Due to Parental High Levels of Worry — 87 Participants
N/A N=945 Effect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChart
Health Care Utilization
Primary: Number of Participants Who Completed Well Child Check Visit — 40; 76; 61 Participants — p=0.000